Structural heart startup Nyra Medical Inc. scooped up $20 million in a series A round co-led by Vensana Capital and a large, unnamed global medical device company. The funds will be used to advance Nyra’s transcatheter heart valve repair technology through early feasibility clinical studies.
When the COVID-19 pandemic effectively shut down travel and conferences starting in the first part of 2020, the general lament was that the lack of face-to-face interaction would hamper biopharma companies’ ability to secure deals and investments. Instead, the opposite happened. Now, coming off two years of record-breaking financing, the biopharma sector is facing an inevitable correction, though a handful of venture capital panelists suggested there’s room for optimism.
Med-tech firms raising money in public or private financings, including: 5th Century Partners, Aziyo, Lumen, Minze Health, Pictorlabs, Radon Medical Imaging, Theralink.
Both the Hong Kong Stock Market and the Shanghai STAR Market have seen med-tech companies, namely Orbusneich Medical Group Holdings Ltd. and Shanghai Genext Medical Technology Co. Ltd., making a rush to be listed by the end of 2022.
RSS
